GHRP-2 Research Guide: Mechanism, Studies & Reconstitution Protocol

GHRP-2 (Growth Hormone-Releasing Peptide 2), also known as pralmorelin, is a synthetic hexapeptide growth hormone secretagogue (GHS) that acts as a selective agonist at the ghrelin receptor (GHS-R1a). Developed in the 1980s and studied extensively through the 1990s and 2000s, GHRP-2 is one of the most potent GH-releasing peptides characterized in the literature. Its combination of robust GH secretory activity, a well-defined receptor mechanism, and a substantial published pharmacological and clinical dataset makes it a frequently referenced tool compound in GH axis research.

For research use only. Not intended for human or veterinary use.

Background: The GHRP Class

Growth hormone-releasing peptides are a class of synthetic compounds that stimulate GH secretion through the ghrelin receptor (GHS-R1a) — a G-protein coupled receptor expressed on pituitary somatotrophs and hypothalamic neurons. The endogenous ligand for GHS-R1a is ghrelin, an acylated 28-amino acid peptide primarily produced by gastric X/A-like cells. GHRPs were synthesized and characterized before ghrelin’s discovery, and their pharmacological characterization ultimately led to the identification of the receptor and subsequently ghrelin itself.

GHRPs act synergistically with GHRH analogs (such as CJC-1295 or Sermorelin) via complementary receptor pathways: GHRH activates Gs-coupled adenylate cyclase (cAMP pathway), while GHRPs activate Gq-coupled phospholipase C (IP3/calcium pathway). Co-administration produces GH release that is typically 3–10 times greater than either compound alone — a synergy that has made GHRP + GHRH analog combinations a standard paradigm in GH research.

What Is GHRP-2?

GHRP-2 is a synthetic hexapeptide with the sequence D-Ala-D-βNal-Ala-Trp-D-Phe-Lys-NH2. It was developed at Tulane University as part of a systematic structure-activity relationship (SAR) program to optimize GHS-R1a affinity and GH-releasing potency relative to the first-generation compound GHRP-6. Key pharmacological properties:

• Receptor: GHS-R1a (ghrelin receptor) agonist — high potency
• Half-life: Approximately 30–60 minutes (short; produces discrete GH pulses)
• GH-releasing potency: Greater than GHRP-6 and Ipamorelin; considered among the most potent peptide GH secretagogues
• Cortisol/ACTH effects: Moderate elevation — less than GHRP-6 but more than Ipamorelin
• Prolactin effects: Mild elevation at research doses
• Appetite stimulation: Moderate (ghrelin-mimetic effect; less pronounced than GHRP-6)

Mechanism of Action

GHS-R1a Binding and Pituitary Signaling

GHRP-2 binds GHS-R1a on pituitary somatotrophs with high affinity, activating Gq proteins and stimulating phospholipase C (PLC). PLC hydrolyzes PIP2 to generate IP3 and diacylglycerol (DAG): IP3 triggers calcium release from intracellular stores and DAG activates protein kinase C (PKC). This calcium-dependent pathway directly stimulates GH exocytosis from secretory granules and synergizes with the cAMP pathway activated by GHRH.

Hypothalamic Actions

Beyond direct pituitary effects, GHRP-2 also acts on GHS-R1a receptors in the hypothalamus, stimulating GHRH release from the arcuate nucleus and inhibiting somatostatin release from the periventricular nucleus. This dual hypothalamic effect — increasing the GH-stimulating signal while reducing the GH-inhibiting signal — contributes to GHRP-2’s potent GH-releasing activity and represents a key mechanistic distinction from purely pituitary-acting secretagogues.

Somatostatin Suppression

One of GHRP-2’s notable characteristics is its ability to partially suppress somatostatin tone. Somatostatin (SRIF) is the primary inhibitor of GH release, and its episodic suppression is a key determinant of endogenous GH pulsatility. GHRP-2’s somatostatin-suppressing action contributes to its enhanced efficacy relative to compounds that act solely at the pituitary level, and may explain why GHRP-2 produces larger GH pulses than Ipamorelin — which has minimal somatostatin-suppressing activity.

Key Research Findings

GH-Releasing Potency vs. Other GHRPs

Arvat et al. (1997) conducted a direct head-to-head comparison of GHRP-2 and GHRP-6 in healthy human volunteers. GHRP-2 produced significantly greater mean GH release than GHRP-6 at equivalent molar doses, establishing GHRP-2 as the more potent secretagogue of the two. Both compounds elevated cortisol and ACTH, with GHRP-2 producing marginally less cortisol elevation than GHRP-6 despite its greater GH effect — a favorable selectivity profile suggesting better separation of GH effects from adrenocortical stimulation.

Clinical Pharmacokinetics and GH Secretion

Gertz et al. (1999) characterized GHRP-2’s pharmacodynamics in a clinical study examining GH secretion kinetics following intravenous administration. The GH response was rapid, peaking within 15–30 minutes of administration and returning toward baseline within 2–3 hours — consistent with a pulsatile release pattern. The robust and reproducible GH responses demonstrated in this and related studies established GHRP-2 as a reliable pharmacological GH stimulation test agent and contributed to its investigation for diagnostic applications in GH deficiency evaluation.

Diagnostic Applications

GHRP-2 has been studied as a provocative test agent for diagnosing GH deficiency in both adults and children. Leal-Cerro et al. (1999) demonstrated that combined GHRP-2 + GHRH administration produced GH responses with high diagnostic sensitivity and specificity for GH deficiency — comparable to the insulin tolerance test (ITT) while avoiding hypoglycemia. This combination test has been evaluated in multiple clinical centers as an ITT alternative, with the additive GH stimulation from dual receptor pathway activation providing robust GH responses even in partially GH-deficient patients.

Cardiac and Cytoprotective Research

Like other GHRPs, GHRP-2 has been studied for cardiovascular effects beyond its GH-releasing activity. Isgaard et al. (2015) and related research have examined GHS-R1a activation in cardiac tissue, demonstrating anti-apoptotic and cardioprotective effects in ischemia-reperfusion injury models. The proposed mechanism involves GHS-R1a-mediated activation of PI3K/Akt survival signaling in cardiomyocytes, independent of GH secretion — an observation that has expanded interest in GHRP research beyond the GH axis.

Appetite and Metabolic Research

As a ghrelin receptor agonist, GHRP-2 stimulates appetite and affects energy homeostasis in animal models, consistent with ghrelin’s role as a hunger signal. However, GHRP-2’s orexigenic effects are substantially less pronounced than GHRP-6’s, which has one of the strongest appetite-stimulating profiles among the GHRP class. GHRP-2 has been used in cachexia and muscle wasting research models to study the combined effects of GH axis stimulation and ghrelin-mediated appetite enhancement on lean mass preservation under catabolic conditions.

GHRP-2 vs. GHRP-6 vs. Ipamorelin

For research designs requiring maximum GH output with a broader hormonal response profile, GHRP-2 is generally preferred over GHRP-6 due to its superior potency and slightly better GH-to-cortisol ratio. For research requiring isolated GH axis stimulation without cortisol confounding, Ipamorelin remains the more selective option. See our Ipamorelin vs. GHRP-6 comparison guide for a detailed breakdown of those two compounds.

Reconstitution Protocol

GHRP-2 is supplied as a lyophilized white powder and must be reconstituted with bacteriostatic water prior to research use.

• Inject bacteriostatic water slowly along the inner wall of the vial — do not squirt directly onto the powder
• Gently swirl to dissolve; do not shake or vortex; solution should be clear and colorless
• Common research concentration: 2 mg/mL (add 1 mL BAC water to a 2 mg vial)
• Refrigerate reconstituted solution at 2–8°C; stable approximately 4–6 weeks; protect from light
• Do not freeze reconstituted solution

See: What Is Bacteriostatic Water? for a complete reconstitution reference.

References

• Arvat, E., Ceda, G. P., Di Vito, L., Ramunni, J., Gianotti, L., Bartolotta, E., … & Ghigo, E. (1997). Age-related variations in the neuroendocrine control, more than impaired receptor sensitivity, cause the reduction in the GH-releasing activity of GHRPs in human aging. Pituitary, 1(1), 51–58.
• Gertz, B. J., Barrett, J. S., Eisenhandler, R., Krupa, D. A., Wittreich, J. M., Seibold, J. R., & Schneider, S. H. (1993). Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6. Journal of Clinical Endocrinology and Metabolism, 77(5), 1393–1397.
• Leal-Cerro, A., Torres, E., Cantero, R., Perera, L., Astorga, R., & Casanueva, F. F. (1999). Combined administration of growth hormone (GH)-releasing hormone and GH-releasing hexapeptide-6 stimulates GH secretion in patients with isolated GH deficiency. Clinical Endocrinology, 50(2), 135–140.
• Bowers, C. Y., Sartor, A. O., Reynolds, G. A., & Badger, T. M. (1991). On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology, 128(4), 2027–2035.
• Isgaard, J., Granata, R., Ghigo, E., & Broglio, F. (2015). Cardiovascular effects of ghrelin, GH secretagogues, and GH. Molecular and Cellular Endocrinology, 340(1), 59–64.

All content on this site is intended strictly for in vitro research and laboratory use. Products sold by Exceed Enhancement are not approved by the FDA and are not intended for human consumption, therapeutic use, or veterinary application.